Salona Global Medical Device Corporation
Salona Global Medical Device — Investor Presentation (December 2022)
17 slides from Salona Global Medical Device's investor presentation, Dec 7, 2022
Slide 1: Corporate Presentation December 2022
CORPORATE PRESENTATION DECEMBER, 2022 SALONA GLOBAL MEDICAL DEVICE CORPORATION
Slide 2: Important: You Must Read Before Continuing
SD (PORTANT GS YOU MUST READ BEFORE CONTINUING IMPORTANT: YOU MUST READ THE FOLLOWING BEFORE CONTINUING. This presentation (the “Presentation") about Salona Medical Device Company (“Salona' or the *“Company’] is dated as of December 1, 2022. Its information in a summary form and does not purport to
Slide 3: Cautionary Note Regarding Forward-Looking Statements
SD | PorTANT GS YOU MUST READ BEFORE CONTINUING ‘CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION AND FORWARD-LOOKING STATEMENTS: Certin statements contained in ths Presentation constitute orwardooking statements and “orwarc-ooking information” within the mesning af the Private Securities Ligat
Slide 4: Important: You Must Read Before Continuing
SD (PORTANT GS YOU MUST READ BEFORE CONTINUING Prospective investors should not place undue reliance on orwarddooking stetements which are based on the information avalible a of the date of this document Forward-looking statements cantained in this document are made ofthe date hereof and, exept as f
Slide 5: U.S. Investor Notice
ED (PORTANT GS YOU MUST READ BEFORE CONTINUI US. INVESTOR NOTICE: This document doesnot constitute an offer to el a the solicitation a an afer to buy, nr shell there be any sale of secures ofthe Company in any juin in whieh an ater, solicitation o sale would be unlawful pri to registration ot qusife
Slide 6: Important: You Must Read Before Continuing
SD (PORTANT GS YOU MUST READ BEFORE CONTINUI bia statutory ight of action i aubjct to the olin) you elect to exercise the right of ation for rescission you wil have no ight faction for damages agsinat the Company; (except with reapeet purchasers reaident in Nova Seti, no action al be commenced to en
Slide 7: The Recovery Science Market and Physical Therapy
THE RECOVERY SCIENCE MARKET AND PHYSICAL THERAPY THE $30B+ AND GROWING RECOVERY SCIENCE & MEDICAL DEVICE INDUSTRY HAS CONSISTENTLY OUTPERFORMED THE MARKET AVERAGE (1) * 1.6 MILLION REGISTERED PHYSICAL THERAPISTS (PT) WORLDWIDE 35 MILLION UNIQUE PATIENTS PER WEEK OR ABOUT 15% OF THE US ADULT POPULATI
Slide 8: Products That Make the Market
PRODUCTS THAT MAKE THE MARKET PREVENTION TREATMENT REHABILITATION + Specialty Supports* + Muscle Stimulation* + Pre-op pee + Athletic Braces* + Wound Care Devices* 2 alee 5 A + Ergonomics* ~ Diabetic Shoes* —_ Bone Growth Stimulators Hoge - Wearables* + DVT Devices a + TENS & NMES* + Post-op Braces
Slide 9: Products Being Sold - Examples
PRODUCTS BEING » SOLD - EXAMPLES Rehabilitation Treatment MUSCLE STIMULATION MUSCLE THERAPY ATHLETIC BRAC! — December 2022 | Page 6
Slide 10: Management Team
MANAGEMENT TEAM LES CROSS IRMAN KEN ZISHOLZ SCOTT ROGOW December 2022 | Page 7 The team leaders operated DJO Global (on the NYSE), the leader in recovery science Blackstone bought out DJO at 3.3x revenues or US$1.6B Les Cross - former CEO of DJO Luke Faulstick - former COO of DJO FINANCIAL ADVISORS
Slide 11: Growth Plan
GROWTH PLAN Capitalize on extensive industry contacts to drive five engines of revenue and profit growth: 1..M8A: A deep pipeline of potential acquisition targets 2. Product Development: Five products under development; one already brought to market in less than 6 months 3._Product IP Acquisition: S
Slide 12: Vertical Integration
VERTICAL INTEGRATION |satona clobat Capturing “Top-to-Bottom” margins through its subsidiaries Through M&A, IP acquisition & product development, SGMD plans to add more distribution channels and medical device products increasing production and maximizing margins SALES AND DISTRIBUTION FDA APPROVED
Slide 13: SGMD Summary
SGMD SUMMARY + $80 million in revenues including last 2 announced acquisitions (DaMar and Biodex)* + 33% reported gross margins for reported QI/Q2; 30%-35% margins expected post DaMar and Biodex integration + $1.4 million in reported adjusted EBITDA fiscal YTD (see Q2 announcement for GAAP reconcili
Slide 14: Review of Biodex Acquisition - Products
REVIEW OF BIODEX ACQUISITION - PRODUCTS Bidoex is a niche brand of physical therapy clinic devices with an IP-based product portfolio including devices for: Isokinetic system 1 Balance | Gait Training 1 Fallprevention 1 — Ergonomic systems
Slide 15: Review of Biodex Acquisition: Terms & Financial Metrics
REVIEW OF BIODEX ACQUISITION: TERMS & FINANCIAL METRICS * The Biodex asset acquisition is highly accretive and is expected to generate $26 mi nin additional annual revenue; comprised of $20 million in revenues from medical device sales at gross margins greater than 30% and of $6 million from a suppl
Slide 16: +L Someta
+L Someta ISXV:SGMD Common shares tradable feat) $3707.779 Enterprise Value: Class AShares 11385425 es as oe ee Earn out shares expected to belssued 71,760,563 ‘s80M ‘Total shares 95,842,767 Sco 92 repartee combines with TEM resets of Bode (eae oy “Yahoo nance 1128122 December 2022 | Page 13
Slide 17: Office
oo000 OFFICE SALONA GLOBAL MEDI DEVICE CORP NA info@salonaglobal.com 6160 INNOVATION WAY ; CARLSBAD, CA & 1 (800) 760-6826 ce) www.salonaglobal.com o0o000 December 2022 | Page 14
Salona Global Medical Device — Investor Presentation (December 2022) on 6ix